GlassScriptPhysician profile
Youssef A Dakka
NPI 1437367497
$5,244.12
in general payments reported to CMS, 2019-2025
32 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2021: $316 · 2022: $1,214 · 2023: $312 · 2024: $1,625 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $981.55 | 2022 | |
| Abbvie INC. | $981.40 | 2022-2025 | Botox, Ubrelvy |
| Ucb, INC. | $757.24 | 2024-2025 | Nayzilam, Briviact, Fintepla |
| Revance Therapeutics, INC. | $634.17 | 2024-2025 | Daxxify |
| Pfizer INC. | $344.76 | 2023-2025 | |
| Allergan, INC. | $238.93 | 2020-2022 | |
| Amgen INC. | $166.76 | 2020-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $132.78 | 2024-2025 | Rexulti |
| Aucta Pharmaceuticals, INC. | $89.82 | 2025 | Motpoly Xr |
| Lundbeck LLC | $88.76 | 2023-2024 | Rexulti |
| Csl Behring | $88.33 | 2020-2025 | Hizentra |
| Tanabe Pharma America, INC. | $82.53 | 2023-2025 | Radicava |
| Axsome Therapeutics, INC. | $80.22 | 2024-2025 | Sunosi, Symbravo |
| Neurelis, INC. | $66.50 | 2023-2024 | Valtoco |
| Amneal Pharmaceuticals LLC | $60.00 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.45 | 2024-2025 | Hyqvia |
| Sk Life Science, INC. | $40.43 | 2023-2025 | |
| Galderma Laboratories, L.P. | $39.18 | 2025 | Dysport |
| Lilly USA, LLC | $35.62 | 2022-2023 | Amyvid |
| Biogen, INC. | $35.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.80 | 2025 | Wainua |
| Livanova USA, INC. | $31.64 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $28.49 | 2025 | |
| Argenx US, INC. | $28.32 | 2025 | Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $26.17 | 2020 | |
| Horizon Therapeutics Plc | $17.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.65 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.72 | 2021 | |
| Janssen Biotech, INC. | $14.69 | 2025 | |
| Celgene Corporation | $13.07 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Dakka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.